Loading...

PODCAST

MAP - Market Access Podcast

Dr. Stefan Walzer

Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world. MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your

business medicine

All Episodes

41:41

What Will It Take to Keep Biotech Growing in Europe,...

MAP - Market Access Podcast ·

2026/10/01

In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Rainer Westermann, Chairman of the Life Sciences Acceleration Alliance (LSAA), to ask whether Europe can remain a globally competitive home for life sciences innovation — and what has to change for new therapies to reach patients.Bringing an investor's lens, Rainer explains why so many promising European companies scale in the US instead: the "valley of death" between great science and a viable business, the

en

39:17

How Do You Build a High-Performing Team in Pharma,...

MAP - Market Access Podcast ·

2026/09/15

In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Maurice Kléber to explore what building a winning team really takes — drawing on 18 years of leadership and a shared love of ice hockey.They discuss why trust and psychological safety are the foundation of any high-performing team, how role clarity and shared accountability turn a group of individuals into a unit, and why talent alone never wins — culture does. Along the way, Dr. Maurice shares the analogies he

en

38:18

Where Does AI Really Add Value in Market Access, Dr....

MAP - Market Access Podcast ·

2026/09/01

Everyone wants AI to click the button for them — the real question is whether you still need to click it at all. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Seye Abogunrin, a health economist at Roche, Switzerland, to move AI in market access from experimentation to execution.They explore where AI adds real value today — drafting dossier text, screening titles and abstracts, extracting data from full-text papers — and why out-of-the-box prompting isn't

en

29:24

Why Should Early Health Economics Move Upstream, Dr....

MAP - Market Access Podcast ·

2026/08/15

By the time most health economists get pulled in, the recipe is already set. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with two industry veterans — Dr. Björn Schwander, Founder of AHEAD GmbH and a specialist in early health economic modeling, and Julie Frappier, senior health economist and Founder of TOWWERS — to make the case for moving early health economics upstream. The conversation reframes value as more than a financial number: the combination of clinical

en

34:58

How Are Data Privacy Laws Delaying Patient Access to...

MAP - Market Access Podcast ·

2026/08/01

This is a repost of a popular episode of MAP - Market Access Podcast, from March 1st 2025.In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data privacy challenges, delays in commercialization, and the future of healthcare data regulation.Learn more about how data privacy laws create barriers for

en

33:02

How Did MFN Turn Swiss Pricing into an Industrial...

MAP - Market Access Podcast ·

2026/07/15

When Bern sets a price, Washington now listens. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Marcel Boller, Pharma and Medtech Expert and Partner at Werder Viganò in Zurich, to unpack why Swiss pricing reform has shifted from a reimbursement question into an industrial policy one.With Switzerland now in the US "Most Favored Nation" (MFN) reference basket, every price negotiated with the BAG (Swiss Federal Office of Public Health) signals straight to US

en

32:08

Is the EU "Launch Obligation" Really as Scary as It...

MAP - Market Access Podcast ·

2026/07/01

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now.They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a marketing authorization is filed, why the so-called "launch obligation" is far from compulsory licensing, and how MFN pricing pressure from the US is forcing

en

37:40

Dynamic Rebates, Drug Tenders & AMNOG: Is Germany...

MAP - Market Access Podcast ·

2026/06/15

Tune in to the newest episode of MAP, the Market Access Podcast, where Dr. Stefan Walzer engages in an insightful discussion with Prof. Dr. Thomas Hammerschmidt, a leading expert in Pharmaceutical Management at the Technical University of Applied Sciences (TH Rosenheim) in Bavaria. Together, they explore the latest proposals influencing AMNOG, pharmaceutical pricing, reimbursement, and market access. Topics include dynamic mandatory rebates, patented drug tenders, price-volume agreements, and their

en

36:20

Wie finanziert Deutschland Gesundheitsinnovation,...

MAP - Market Access Podcast ·

2026/06/08

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, insbesondere Orphan Drugs, und welche

en

39:14

What lessons can Market Access teams learn from an...

MAP - Market Access Podcast ·

2026/06/01

From Olympic ice to AI-powered leadership: What can Market Access teams learn from elite sports? In the 111+1 anniversary episode of MAP – the Market Access Podcast, Dr. Stefan Walzer interviews Livia Altmann, a former Swiss Olympic ice hockey player who has transitioned into a leadership and "Human Intelligence 2.0" expert. Together, they explore how mental training, consistency, and energy management drive success in both elite sports and the business world—and why, in an AI-driven era, execution

en

30:36

How Are UK NICE and US IRA/MFN Rewriting Global...

MAP - Market Access Podcast ·

2026/05/15

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer speaks with Sreeram Ramagopalan, a global expert at the intersection of biotech value, HTA, real‑world evidence and market access. Together they unpack how the UK NICE threshold increase (from £20–30k to £25–35k per QALY) and US reforms (IRA, MFN) are quietly rewriting the rules for global launch sequencing and pricing strategy.They discuss why the US is no longer an isolated “free pricing” island, how UK and EU prices can

en

38:40

How Can Europe Move from Innovation Paradox to...

MAP - Market Access Podcast ·

2026/05/01

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer engages with Swiss healthcare strategist Cuno Moser to explore Europe's "innovation paradox" in healthcare. Despite its strengths in research, data quality, and clinical expertise, Europe struggles to transform pilot projects into scalable, reimbursable solutions. With over 27 fragmented reimbursement systems in the EU and in Switzerland, significant barriers impede progress in digital health, medtech, and AI-driven care

en

38:57

Are primary research platforms adapting to payer...

MAP - Market Access Podcast ·

2026/04/15

In the latest episode of the MAP – Market Access Podcast, Dr. Stefan Walzer speaks with pricing and access expert Shrutya Bhalla about how primary research must evolve in an era of AI, policy shocks, and accelerating market complexity. The key takeaway: high‑quality primary research is no longer just about collecting insights – it must enable real strategic choices on pricing, access, launch sequencing, and evidence generation. This means moving from slow, static projects to continuous,

en

40:32

How Can Political Leadership Turn Health into an...

MAP - Market Access Podcast ·

2026/04/01

In this episode of the MAP – Market Access Podcast, Dr. Stefan Walzer speaks with Hatice Küçük Beton, Executive Director of the G20 Health and Development Partnership, about how to make global health truly investable – and keep it on the political agenda once the immediate crisis fades. They explore why high-level leadership, from Angela Merkel’s role during Germany’s G20 presidency to Japan’s joint health–finance initiative, was crucial in moving health from a “social cost” to a strategic economic

en

34:42

Is Europe Still More Attractive Than the US, China,...

MAP - Market Access Podcast ·

2026/03/15

In the latest Market Access Podcast episode, host Stefan Walzer sits down with Bernard “Bernie” Bichsel – one of Europe’s most experienced voices in medtech regulation and former Head of the Medical Devices Division at Swissmedic – to unpack how regulation and market access truly fit together. They discuss why medical device regulation in Europe is still young compared to pharma, why the MDR/IVDR “notified body bottleneck” is largely yesterday’s problem, and how smart startups build regulatory

en

39:40

From Necessary Tasks to New Insights: How Can AI Act...

MAP - Market Access Podcast ·

2026/03/01

In this episode, Stefan Walzer talks with experienced Market Access manager Helmut Butscher about concrete AI applications across the full Market Access value chain. They explore how AI accelerates systematic literature reviews, unlocks real‑world evidence from complex data sources, supports HTA dossier preparation, and enables smarter decisions on pricing, reimbursement and global launch sequencing. They also address the limits and risks of AI in a highly regulated setting – from opaque HTA and

en

52:58

Can Innovative Contracting Turn High‑Cost Therapies...

MAP - Market Access Podcast ·

2026/02/15

In this thought‑provoking Market Access Podcast episode, host Stefan Walzer sits down with Omar Ali – Head of Payers at Vipora, former NICE advisor, and one of the sharpest minds in drug pricing and innovative contracting to unpack where drug pricing and reimbursement are really heading.They explore why cost‑effectiveness thresholds are making market access tougher than ever, how uncertainty around CAR‑T, gene therapies and orphan drugs fuels the “orphan bubble”, how innovative contracting and

en

42:42

What Makes Australia’s HTA Approach to Equity and...

MAP - Market Access Podcast ·

2026/02/01

In this Market Access Podcast episode, Dr. Stefan Walzer sits down with Prof. Zanfania Ademi, a health economist at Monash University, to explore how Australia’s healthcare system is tackling key issues in market access and health technology assessment. Discover how Australia blends international approaches and new methods being developed by Zanfina and her team like distributional cost-effectiveness and productivity-adjusted life years to advance equity and value in healthcare. Tune in for fresh

en

34:48

No Decisions for Us, Without Us: Why Patient Advocacy...

MAP - Market Access Podcast ·

2026/01/15

In this episode of the Market Access Podcast, Erica Bersin—founder of ERO Health Communications—joins Dr. Stefan Walzer to discuss the changing role of patient involvement in healthcare. Drawing on her experience in both Europe and the U.S., Erica explains how single-payer systems make patient engagement easier, while the U.S. faces more challenges but also unique advocacy opportunities. She highlights the work of organizations like PCORI and the need for better data transparency.The episode

en

35:02

Can VR and AR Finally Break Through the Barriers in...

MAP - Market Access Podcast ·

2025/12/15

In this episode of the Market Access Podcast, Dr. Stefan Walzer sits down with strategy consultant and XR advocate Günter Illert to explore how virtual, augmented, and extended reality are reshaping healthcare—from patient training and pain therapy to surgical planning and medtech education.Learn how cross-sector collaboration and early adoption—especially outside traditional reimbursement systems—can unlock the full potential of immersive technology in medicine. A must-listen for innovators, health

en

121 results

Similar Podcasts

TaxTalent.com The Golden Rule Podcast

Adam Golden

TaxTalent.com Podcast

Tony Santiago

Digital Finance Analytics (DFA) Blog

Martin North

The Smashi Business Show

Augustus Media

Dagen med Di

Dagens industri